Search
Walvax Biotechnology: Subsidiary’s COVID-19 mRNA Vaccine Receives Approval for Market Release
1 day ago /
Read about 0 minute
Author：小编
On September 10, 2026, Yuxi Walvax, a fully-owned subsidiary of Walvax Biotechnology, was granted the 'Drug Registration Certificate' by the National Medical Products Administration for its third-generation COVID-19 mRNA vaccine. This vaccine, developed based on the S protein of the Omicron JN.1 variant, is specifically designed for preventing COVID-19 infection in individuals aged 18 and over. Walvax Biotechnology expects that this approval will not significantly influence its financial results for the year 2026.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
